There is no specific treatment of acute myocarditis, especially during the inflammatory
period. Interleukin (IL) is specifically involved during this period and play a role in
myocardial oedema. ANAKINRA, an IL-1β Blocker, is a new treatment that has never been
evaluated in myocarditis. The benefit for the patient could be important with a reduction of
heart failure and ventricular arrhythmias.
Hypothesis : ANAKINRA in addition to standard therapy for treatment of Acute Myocarditis is
superior to standard therapy based on an association of beta-blockers and
Angiotensin-Converting-Enzyme inhibitor (ACE).